Heart pump could protect patients during risky stent procedures
NCT ID NCT05003817
First seen Feb 21, 2026 · Last updated Jun 20, 2026 · Updated 19 times
Summary
This study tests a temporary heart pump in 300 high-risk patients with severe coronary artery disease and weak heart muscle. The pump supports the heart during stenting to prevent failure. Researchers want to see if it reduces death, stroke, or heart-related hospital stays.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CORONARY ARTERY DISEASE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Guy's and St Thomas' NHS Foundation Trust
London, SE1 7EH, United Kingdom
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
percutaneous left ventricular unloading device (a temporary heart pump)
What this could lead to
If successful, this could provide a safer way to perform stenting in high-risk patients, reducing serious complications like heart failure or death.
What could go wrong
The device itself carries risks like bleeding or leg artery damage, and it is expensive. This is a Phase 3 trial, so results are not yet confirmed.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.